Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) EBIT Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBIT Margin for 11 consecutive years, with 7069.13% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 1161047.0% to 7069.13% in Q3 2025 year-over-year; TTM through Dec 2025 was 35851.25%, a 3573771.0% decrease, with the full-year FY2025 number at 35851.25%, down 3573656.0% from a year prior.
  • EBIT Margin was 7069.13% for Q3 2025 at Cartesian Therapeutics, up from 7319.13% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 7069.13% in Q3 2025 to a low of 7319.13% in Q2 2025.
  • A 5-year average of 452.9% and a median of 50.59% in 2022 define the central range for EBIT Margin.
  • Biggest YoY gain for EBIT Margin was 1161047bps in 2025; the steepest drop was -736048bps in 2025.
  • Cartesian Therapeutics' EBIT Margin stood at 13.62% in 2021, then plummeted by -471bps to 50.59% in 2022, then crashed by -769bps to 439.54% in 2023, then skyrocketed by 827bps to 3197.49% in 2024, then skyrocketed by 121bps to 7069.13% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EBIT Margin are 7069.13% (Q3 2025), 7319.13% (Q2 2025), and 5472.25% (Q1 2025).